December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
August 2016 in “Journal of Investigative Dermatology” Dutasteride improved hair density and thickness in men not helped by finasteride, with minimal side effects.
August 2016 in “Journal of Investigative Dermatology” Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride works better than finasteride for hair growth with similar side effects.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
March 2016 in “Korean Journal of Medicine” Doxazosin can cause male breast growth and milk production.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
The article concludes that understanding the causes of hair loss and using continuous treatments like minoxidil and finasteride can help manage it, despite potential side effects.
January 2016 in “The Korean Journal of Internal Medicine” Doxazosin may cause breast enlargement and pain in men.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
September 2015 in “한국임상약학회지” The document's conclusion cannot be determined without content.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
January 2015 in “Вестник дерматологии и венерологии” Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
September 2014 in “PubMed Central” BPH treatments can cause sexual side effects affecting quality of life.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
January 2014 in “Anales Médicos de la Asociación Médica del Centro Médico ABC” The treatment effectively promoted hair growth with minimal side effects.
The models can help find better inhibitors for conditions like baldness and prostate disorders.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
December 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.